Factors in Selecting Novel Therapy for Patients With EGFR Exon20+ NSCLC

July 24, 2023

By Joshua K. Sabari, MD
Misako Nagasaka, MD

Video

Following their review of data behind amivantamab and mobocertinib in EGFR Exon20+ non–small cell lung cancer, expert oncologists consider factors that help to inform treatment selection.

EP: 1.Paradigm of NGS Testing in Patients With Advanced NSCLC

EP: 2.Uncommon EGFR Mutations in Advanced Non–Small Cell Lung Cancer

EP: 3.First- and Second-Line Treatment Options for EGFR Exon20+ NSCLC

EP: 4.Trial Data and Experience With Amivantamab in EGFR Exon20+ NSCLC

EP: 5.EGFR Exon20+ NSCLC: Trial Data With Mobocertinib

Now Viewing

EP: 6.Factors in Selecting Novel Therapy for Patients With EGFR Exon20+ NSCLC

EP: 7.Advanced NSCLC: CNS Penetration With Novel EGFR TKI Therapy

EP: 8.Evolving Management of EGFR Exon20+ NSCLC: Future Directions in Care

EP: 9.Amivantamab vs Mobocertinib in Exon 20 NSCLC

EP: 10.Frontline Forum: Testing and Targeted Therapy in EGFR Exon20+ NSCLC

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!